Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boat, You could not convert your ADS into ten regular shares even before these actions.
boatlife Member Level Thursday, 04/30/15 09:03:48 AM
Re: BackTheTruckUp post# 590
Post # of 606
we did..u cant convert into 10 common shares now if u wanted to, so we got shafted outta 9 common shares with the 10-1 rev split
Boat, That's not how it works. One ADS has always been composed of a "bundle" of ten regular shares. When they r/s the ten regular shares into one, we holding ADSs will have nothing happen to our ADSs, which will represent the same proportion of corporate ownership.
Yes, some folks can panic who pay insufficient attention to what is going on, but there is no rational basis for that.
boatlife Member Level Wednesday, 04/29/15 08:48:44 PM
Re: BackTheTruckUp post# 581
Post # of 605
just burns that we got shafted out of 9 shares per ADS
Hope,
If we were consistently in the black, $3/sh. If we manage to keep the profit increasing each quarter yoy, then higher. Buyout would be higher than that.
Marasprint, Last time, MARA's price dropped for no apparent reason and we got it removed from Fidelity, which is NOT the rater. This time I called it to Jason's attention at MARA, and this was his response (pretty much parallel to yours) regarding Thomson-Reuters:
Steve,
I would not give it much, if any consideration. I personally don’t view it as credible or meriting much thought. Based on their track record of mistaking symbols and companies, nothing would surprise me.
Best
J
I don't know if this is a reapeat of the earlier misidentification but I found this on Fidelity:
Thomson Reuters/Verus resumes coverage for MARATHON PATENT GROUP INC with SELL recommendation.
BY Investars Analyst Actions - public
— 1:04 PM ET 04/27/2015
On April 27, 2015 Thomson Reuters/Verus resumed coverage for MARATHON PATENT GROUP INC ( MARA
) with a SELL recommendation.
WH, To contact other IHub members off this board, remember you have "happy hour," free use of the private messaging feature from 4-5 pm ET on Fridays. You can send a PM to anyone (unlimited) on the board, and give them an email (preferably not your main one) to contact you anytime
Edit: You could do as was suggested - see where they are invested - but you also could ask them for their elevator pitch on those stocks.
I have MNOV in the wife's IRA, at about 10 percent of the total. The other stock is mostly in mine, at about 33 percent of my Roth. So you see my confidence level.
Yes, the allocation process can be complicated. EDIT: PLMK if you want some light bedtime reading.
And I just did buy a bit more.
Well, if you measure confidence as the amount invested, the other has 10X my investment here in MNOV. Perhaps I should buy even more MNOV and go partway toward evening them up?
As much confidence in MNOV as you have in CTIX?
Even the proverbial blind pig.... No, I may not be fancy doing it and only risked a portion of our position, but this time it worked.
I have utmost confidence in MNOV as the little engine that could.
Thank you. More dumb luck than anything else.
I replaced all the shares I sold at $5.35 between $3.95-4.01. Looking for more.
Andy, Please keep posting your articles and snippets. A lot of us do care.
They will be authorized by our positive vote and can do it - or not - when it suits them. Jason Napodano told me they have been trying to get the company to do this and that it will broaden the marketability of the shares. I posted precisely what he said earlier.
I was waiting for mid-90s, but pulled the trigger at under 99 today.
You are not reading it wrong.
Not in any of those, but I don't trust The Street at all. My stock is smaller, but certainly has lots of liquid assets.
Now I just need a certain spirits company in which I invest to send out a bottle of their good stuff.
When I held shares in a long distance company, they would send out X (do not recall the number) minute cards for calling. Again, a long time ago.
Titan, Got the card as well. Surprised you've never received at least annual reports or proxy materials...but then I'm probably way older. Used to get proxies by stone tablet.
Well, I guess he was either on a mission to spread FUD, or so desperate for his pennies-per-click that he won't mind the thrashing he'll get in comments.
I attempted a brief response. Article raises the old canard against Menon's resume, among other things. Certainly intent on raising doubt about CTIX. Can't even spell Cellceutix correctly.
Thank you for sharing your analysis!
CMC, So is it also fair to say that some of those folks are really still operating in the dark? At least to the extent that their stories are true.
CallMeCrazy Monday, 04/20/15 02:50:26 PM
Re: someconcerns post# 98391
Post # of 98406
Sometimes the mind can be like the eye of an owl, the more light you put on it, the smaller it gets.
You and Rule are quite welcome. I've found Jason to be approachable and open as long as you are asking about one of his stocks. Friendly otherwise, but the guy is really busy with all those in-depth articles.
I contacted Jason Napodano, who responded thusly:
someconcerns
Comments (124)
Jason, Have you heard about the special shareholder meeting to authorize a "consolidation" - which I think most of us would call a reverse split? I saw this on Fidelity, where they were asking me to vote.
19 Apr, 10:38 AM
Reply! Report AbuseLike0
Jason Napodano, CFA , contributor
Comments (970)
Author’s reply » It's so they can reverse split the stock and then uplist to the NASDAQ. You should vote 'Yes'. CYNAF getting on the NASDAQ would allow for significantly more institutional buying in the open market, as well as increased liquidity and valuation expansion
Any way you can make that required reading for certain people posting on the board?
It is now posted on the company's site, along with a link to Sedars. Although it is buried pretty well. There appears to not have been a press release.
TJ, Yes, aware of the trial using both Keytruda and ONCS participation. Long-time holder of ONCS myself. I am sure both articles had the same study as their genesis. GLTAL
trading.jeff Sunday, 04/19/15 07:48:23 PM
Re: someconcerns post# 29519
Post # of 29527
$ONCS Merck has supplied its drug, Keytruda, to one of the trials that OncoSec is participating in. No doubt, Merck will be watching closely, as it will be watching the other trials in which Keytruda is being tested.
BTW, I came across this article in the WSJ re: Keytruda and melanoma:
Merck’s Keytruda Shows Improved Survival Odds in Melanoma
Immunotherapy displayed better survival rates compared with Bristol-Myers’s Yervoy
http://www.wsj.com/articles/mercks-keytruda-shows-improved-survival-odds-for-melanoma-patients-1429448169
The article is dated today but, wasn't there a trial, involving Keytruda, that was stopped early because Merck's drug showed promising results over a rival's drug? Isn't this article discussing the same?
Yes, the name Ribas jumped out at me.
I did not say that they should have been mentioned.
However, with Merck and others apparently neck and neck with response/nonresponse rates, ONCS - or frankly someone else's electroporation - could give one of the companies a leg up on the others.
If people react to the CYNAF r/s like they do to most r/s, I'm thinking below a buck. One of the chartists might opine here.
ONCS not mentioned, but will ONCS electroporation allow Merck's drug to surpass competitors?
http://www.forbes.com/sites/matthewherper/2015/04/19/merck-cancer-drug-shines-against-skin-lung-cancer/?utm_source=followingimmediate&utm_medium=email&utm_campaign=20150419
EB, I wouldn't sweat it with CYNAF. We are too close to events which should give us a good rate of return
However, if you want to your shares cheaply....
Rule, Thank you.
Crude, Thanks. A quick 10 percent gain is nothing to sneeze at.
Not on the corporate site or any other site I can think of, but there might be another buying opp coming up..
Right. Could not find any new info regarding this on the TSE.
I see nothing at SEC or Nasdaq - at least where I know how to look.
My guess is they filed late on Friday and Fidelity was the only entity posting the stuff on a timely basis. Maybe Monday for SEC and Nasdaq, after they put the stuff into their system.
CHM, I saw no more detailed proxy materials and the only added info is on who to vote for and the reaffirmation of the auditor, which given it is Ernst and Young, gives me some comfort. This is from the ballot, which on Fidelity's site is under portfolio/statements/proxy materials. Special meeting is what it says. Can't post link.
I wasn't in CYNAF until after the last consolidation, but this sure sounds like preparing for uplisting to get the price up and then sell it.
I took a peek at the stockh...se site to see if the have anything. Nothing. Maybe someone could look at the SEC filings.